Press Releases

Mar 16, 2026 6:00am EDT

Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01

Mar 03, 2026 6:00am EST

Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01

Feb 24, 2026 6:00am EST

Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026

Jan 27, 2026 6:00am EST

Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy

Jan 22, 2026 6:00am EST

Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01

Dec 29, 2025 6:00am EST

Greenwich LifeSciences Extends Lock-up of Directors and Officers to September 30, 2026

Dec 22, 2025 6:00am EST

Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy

Dec 15, 2025 6:00am EST

Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01

Dec 08, 2025 6:00am EST

Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01

Dec 03, 2025 6:00am EST

Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date